title: Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography.
abstract: Although statins have been shown to prevent contrast-induced acute kidney injury in patients with acute coronary syndromes, the benefit of statins is not known for patients at high risk for nephropathy who undergo elective coronary angiography. Two hundred twenty consecutive statin-naive patients with chronic kidney disease (estimated glomerular filtration rate <60 ml/min/1.73 m(2)) who underwent elective coronary or peripheral angiography were randomly assigned to receive rosuvastatin (40 mg on admission, followed by 20 mg/day; n = 110) or no statin treatment (control group, n = 110). Contrast-induced acute kidney injury was defined by an absolute increase in serum creatinine of ≥0.5 mg/dl or a relative increase of ≥25% measured 48 or 72 hours after the procedure. Contrast-induced acute kidney injury occurred in 15 patients (7.2%), 9 (8.5%) in the control group and 6 (5.8%) in the rosuvastatin group (p = 0.44). The incidences of adverse cardiovascular and renal events (death, dialysis, myocardial infarction, stroke, or persistent renal damage) were similar between the two groups at follow-up. In conclusion, rosuvastatin did not reduce the risk for contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients who underwent coronary and peripheral vascular angiography.
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey. Electronic address: drokayabaci@hotmail.com.
authors: Okay
authors: O
authors: Abaci
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Alev
authors: A
authors: Arat Ozkan
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Cuneyt
authors: C
authors: Kocas
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Gokhan
authors: G
authors: Cetinkal
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Osman
authors: O
authors: Sukru Karaca
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Onur
authors: O
authors: Baydar
authors: Department of Biochemistry, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Aysem
authors: A
authors: Kaya
authors: Department of Cardiology, Istanbul University Cardiology Institute, Istanbul, Turkey.
authors: Tevfik
authors: T
authors: Gurmen
mesh_terms: D054058:Acute Coronary Syndrome / Q000000981:diagnostic imaging* / Q000188:drug therapy; D058186:Acute Kidney Injury / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D000368:Aged; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D003287:Contrast Media; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium